Presentation

Company Profile
BioArctic is a biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, with primary focus on Alzheimer’s disease and Parkinson’s disease. It was founded in 2003 based on research from Uppsala University, Sweden and is nearing a phase 3 readout (Sep2022) for its lead Alzheimer’s drug lecanemab (BAN2401) partnered with Eisai and Biogen. The company is rapidly advancing a rich R&D pipeline within multiple CNS indications and is one of few companies worldwide advancing a highly promising blood-brain-barrier (BBB) technology.

Recent highlights
The controversial approval of Biogen’s aduhelm in June 2021 sparked a renewed interest in Alzheimer’s and has been responsible for the strong YTD performance of the stock (up >40%) while the sector has performed weak. Also, in June, the FDA granted breakthrough therapy designation for lecanemab in Alzheimer’s which will facilitate and speed-up regulatory approval processes. Last month BioArctic’s partner Eisai presented the latest data from lecanemab’s clinical program, including baseline characteristics of the phase 3 trial in preclinical (asymptomatic) Alzheimer’s patients and the phase 3 clarity study (early Alzheimer’s disease. The data showed that the baseline characteristics largely resembled those of the phase 2 trial.

Outlook
BioArctic’s cash reserves of a bit short of SEK 1bn are allowing the company to move the rich early-stage pipeline ahead. According to Eisai, results from the Ph3 Clarity AD study with BAN2401 are expected in Sep2022.